# Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece

> **NCT02626013** · — · COMPLETED · sponsor: **Genesis Pharma S.A.** · enrollment: 156 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02626013
- **Lead sponsor:** Genesis Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-12
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626013, "Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02626013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*